A randomized, placebo-controlled, double-blinded clinical trial of colchicine to improve vascular health in people living with HIV

Conclusions: In PWH with no history of CAD, low-dose colchicine was well tolerated but did not improve impaired coronary endothelial function, a predictor of cardiovascular events. These findings suggest that this anti-inflammatory approach using colchicine in PWH does not improve vascular health, the central, early driver of coronary atherosclerosis.
Source: AIDS - Category: Infectious Diseases Tags: CLINICAL SCIENCE Source Type: research